As we age, protecting cognitive health naturally becomes a concern not only for the individuals experiencing it but also for families and communities. Fortunately, new research offers a promising glimpse of early detection in a way that is compassionate, accessible, and forward-thinking. At The Kensington White Plains, we have always believed that early clarity paired with thoughtful support forms the foundation of well-being.
A Three-Minute Test That Could Reveal Alzheimer’s Early
Scientists at the Universities of Bath and Bristol have developed a brief, passive test nicknamed “Fastball” that may identify early signs of Alzheimer’s years before a formal diagnosis. The test takes just three minutes, using a simple EEG headset to record the brain’s automatic responses while participants view a rapid series of flashing images. This approach removes the stress of traditional assessments by requiring no active responses from the user.
In a study involving 106 participants, including those with amnestic mild cognitive impairment (MCI), the Fastball test reliably detected subtle memory impairments especially in those at elevated risk for Alzheimer’s. Perhaps most importantly, researchers demonstrated that the test works effectively in a home environment, not just in clinical settings.
Researchers hope Fastball could significantly reduce the delay in diagnosis which may otherwise span decades, providing a vital window for early intervention.
Why Earlier Detection Matters More Than Ever
Early detection matters now more than ever because recent treatments like donanemab and lecanemab tend to deliver the best results when administered in the earliest stages of Alzheimer’s. However, many people miss this opportunity especially as one in three individuals living with dementia remains undiagnosed.
The accessibility of Fastball is its greatest strength. Since it is passive and objective, it bypasses language, education, or stress-related barriers, making it more equitable across diverse populations. Funded at approximately £1.5 million, Fastball is currently being tested with 1,000 patients in Bristol marking a major step toward widespread adoption.
While Fastball does not differentiate Alzheimer’s from other types of cognitive decline, it serves as an invaluable red flag prompting further testing, imaging, or biomarker analysis when early memory changes arise.
Putting Research Into Daily Life at The Kensington White Plains
At The Kensington White Plains, research like Fastball’s development aligns with our core vision: knowing what is happening sooner, so support and peace of mind can follow. While residents and families navigate health journeys, we believe in offering both innovative insight and heartfelt clarity.
If protecting cognitive health matters to you or a loved one, consider calling life here where respect, connection, and involvement guide every moment. Contact us today to speak to an expert who can help you find out what’s best for you or your loved one.